Role of Shenfu Injection (参附注射液) in rats with systemic inflammatory response syndrome

Jin Wang; Li-fen Qiao; Guang-tian Yang

doi:10.1007/s11655-008-0051-2

Your Location：

Home >

Browse articles >

Role of Shenfu Injection (参附注射液) in rats with systemic inflammatory response syndrome

OriginalPaper | Updated：2021-08-27

- Role of Shenfu Injection (参附注射液) in rats with systemic inflammatory response syndrome
- Role of Shenfu Injection (参附注射液) in rats with systemic inflammatory response syndrome
- 中国结合医学杂志（英文版） 2008年14卷第1期页码：51-55
- Affiliations：
  
  1. Department Emergency of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
  2. Department Respiratory of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
- Author bio：
- Funds：
  
  Supported by a Grant from Hubei Province Science and Technique Foundation (No. 2003AA301C51)
- DOI：10.1007/s11655-008-0051-2
  中图分类号：
- 纸质出版日期：2008，
  
  网络出版日期：2008-6-21，
Scan for full text
Wang, J., Qiao, Lf. & Yang, Gt. Role of Shenfu Injection (参附注射液) in rats with systemic inflammatory response syndrome., Chin. J. Integr. Med. 14, 51–55 (2008). https://doi.org/10.1007/s11655-008-0051-2

Jin Wang, Li-fen Qiao, Guang-tian Yang. Role of Shenfu Injection (参附注射液) in rats with systemic inflammatory response syndrome[J]. Chinese Journal of Integrative Medicine, 2008,14(1):51-55.
Wang, J., Qiao, Lf. & Yang, Gt. Role of Shenfu Injection (参附注射液) in rats with systemic inflammatory response syndrome., Chin. J. Integr. Med. 14, 51–55 (2008). https://doi.org/10.1007/s11655-008-0051-2 DOI：

Jin Wang, Li-fen Qiao, Guang-tian Yang. Role of Shenfu Injection (参附注射液) in rats with systemic inflammatory response syndrome[J]. Chinese Journal of Integrative Medicine, 2008,14(1):51-55. DOI： 10.1007/s11655-008-0051-2.

摘要

To investigate the role of Shenfu Injection (参附注射液

SFI) in rats with systemic inflammatory response syndrome (SIRS). The SIRS rat model was induced by the intravenous injection of lipopolysaccharide (LPS). Forty-five male Wistar rats were randomly divided into 3 groups

the sham operative control group (control group

n=5)

the SIRS model group (model group

n=20) and the SFI treatment group (SFI group

n=20). LPS was injected through the external jugular vein (12 mg/kg

6 mg/mL) to all rats except for those in the control group

and SFI (10 mL/kg) was given to those in the SF group only once through intraperitoneal injection

while the normal saline (10 mL/kg) was given to those in the model group. For those in the control group

normal saline was given through the external jugular vein (2 mL/kg) and intraperitoneal injection (10 mL/kg). Then

rats in the model group and SFI group were divided into 4 subgroups according to the time points

i.e.

1 h

2 h

4 h and 6 h subgroups

5 rats in each group. The activity of nuclear factor of κ B (NF-κ B) of in blood mononuclear cells and the plasma levels of tumor necrosis factor-α (TNF-α) and interleukin 6-(IL-6) were determined using enzyme-linked immunoabsordent assay (ELISA) at 1 h

2 h

4 h and 6 h after modeling. Histopathologic changes of the lung and liver were observed under a light microscope. Compared with the control group

the activity of NF-κ B in mononuclear cells and the plasma level of TNF-α were obviously increased at each time points (all P<0.01)

reaching the peaks at 2 h after modeling. The plasma level of IL-6 increased gradually as time went by in the model group (P<0.01). Pathological examination showed pulmonary alveoli hemorrhage

edema and inflammatory cell infiltration in the lung tissue

and angiotelectasis

congestion

and local necrosis in the liver tissue in the model group. Compared with the model group

the activity of NF-κ B and the levels of TNF-α and IL-6 in plasma decreased significantly in the SFI group (P<0.01)

and the pathological injury in the lungs and liver was significantly alleviated. SFI plays a protective role by inhibiting the activity of NF-κB

and reducing the expressions of TNF-α and IL-6 in SIRS rats.

Abstract

To investigate the role of Shenfu Injection (参附注射液

the sham operative control group (control group

n=5)

the SIRS model group (model group

n=20) and the SFI treatment group (SFI group

n=20). LPS was injected through the external jugular vein (12 mg/kg

6 mg/mL) to all rats except for those in the control group

and SFI (10 mL/kg) was given to those in the SF group only once through intraperitoneal injection

while the normal saline (10 mL/kg) was given to those in the model group. For those in the control group

normal saline was given through the external jugular vein (2 mL/kg) and intraperitoneal injection (10 mL/kg). Then

rats in the model group and SFI group were divided into 4 subgroups according to the time points

i.e.

1 h

2 h

4 h and 6 h subgroups

2 h

4 h and 6 h after modeling. Histopathologic changes of the lung and liver were observed under a light microscope. Compared with the control group

the activity of NF-κ B in mononuclear cells and the plasma level of TNF-α were obviously increased at each time points (all P<0.01)

reaching the peaks at 2 h after modeling. The plasma level of IL-6 increased gradually as time went by in the model group (P<0.01). Pathological examination showed pulmonary alveoli hemorrhage

edema and inflammatory cell infiltration in the lung tissue

and angiotelectasis

congestion

and local necrosis in the liver tissue in the model group. Compared with the model group

the activity of NF-κ B and the levels of TNF-α and IL-6 in plasma decreased significantly in the SFI group (P<0.01)

and the pathological injury in the lungs and liver was significantly alleviated. SFI plays a protective role by inhibiting the activity of NF-κB

and reducing the expressions of TNF-α and IL-6 in SIRS rats.

关键词

Shenfu InjectionSystemic Inflammatory Response Syndromemononuclear cellslipopolysaccharidenuclear factor-κBtumor necrosis factor-αinterleukin-6

Keywords

Shenfu InjectionSystemic Inflammatory Response Syndromemononuclear cellslipopolysaccharidenuclear factor-κBtumor necrosis factor-αinterleukin-6

references

Christman JW, Lancaster LH, Blackwell TS. Nuclear factor κ B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intens Care Med 1998;24:1131–1138.

Abraham E. Nuclear factor-κ B and its role in sepsisassociated organ failure. Infect Dis 2003;187(Suppl 2): S364–S369.

Taniguchi T, Kanakura H, Yamamoto K. Effects of posttreatment with propofol on mortality and cytokine responses to endotoxin-induced shock in rats. Crit Care Med 2002;30:904–907.

de Rossi LW, Brueckmann M, Rex S, et al. Xenon and isoflurane differentially modulate lipopolysaccharideinduced activation of the nuclear transcription factor κB and production of tumor necrosis factor-alpha and interleukin-6 in monocytes. Anesth Analg 2004;98:1007–1012.

Hu S, Sheng ZY, Zhou BT. The advance of MODS animal model research. Chin Crit Care Med (Chin) 1999;11(8):504–507.

Taniguchi T, Kidani Y, Kanakura H, et al. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med 2004;32:1322–1326.

Bohrer H, Qiu F, Zimmermann T, et al. Role of NF-κB in mortality of sepsis. J Clin Invest 1997;100:972–985.

Paterson RL, Galley HF, Dhillon JK, et al. Increased nuclear factor κB activation in critically ill patients who die. Crit Care Med 2002;28:1047–1051.

Blackwell TS, Christman JW. The role of nuclear κB in cytokine gene regulation. Am J Respir Cell Mol Biol 1997;17:3–9.

Kim PK, Deutschman CS. Inflammatory responses and mediators. Surg Clin North Am 2000;80:885–894.

Xiao L, Wang ZQ. The development of cytokines in infect shock. Foreign Med Sci: Section Pathophysiol Clin Med (Chin) 2003;23(1):100–102.

Hu G, Liu XY, Xia ZY, et al. Effect of Shen-Fu Injection on expression of nuclear factor-κB, ICAM-1, iNOS and TNF-α after ischemia-reperfusion of intestinal mucosa in rats. J Tongji Univ (Med Sci, Chin) 2003;24(5):381–384.

FULL TEXT LINK

More>

浏览量

339

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Effect of Reduqing ( ) on endotoxin-lnduced production of tissue factor and cytokines in human whole blood) on endotoxin-lnduced production of tissue factor and cytokines in human whole blood

Effects of Modified Sanhuang Decoction (加味三黄汤) enema on serum tumor necrosis factor-α and colonic mucosa interleukin-1β, interleukin-6 levels in ulcerative colitis rats

Effect of Xuezhikang Capsule (血脂康胶囊) on serum tumor necrosis factor-α and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia

Clinical study of trilogy detoxicating therapy combined with routine Western medicine on patients with chronic renal failure

Intervention effect of Jianxin Decoction on serum cytokine level of congestive heart failure patients